TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+2.9%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.56B
AUM Growth
+$2.56B
(-2.7%)
Cap. Flow
-$98.6M
Cap. Flow
% of AUM
-3.86%
Top 10 Holdings %
Top 10 Hldgs %
40.31%
Holding
186
New
9
Increased
28
Reduced
31
Closed
20
Top Buys
| 1 |
Merck
MRK
|
$20.3M |
| 2 |
Amgen
AMGN
|
$13.5M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$13.2M |
| 4 |
Insulet
PODD
|
$12.6M |
| 5 |
Tenet Healthcare
THC
|
$12.1M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$35.4M |
| 2 |
Cigna
CI
|
$24.2M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$21.6M |
| 4 |
Bristol-Myers Squibb
BMY
|
$13.1M |
| 5 |
UnitedHealth
UNH
|
$13.1M |
Sector Composition
| 1 | Healthcare | 96.11% |
| 2 | Real Estate | 2.09% |
| 3 | Industrials | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
DOC
51
DELISTED
PHYSICIANS REALTY TRUST
DOC
| $12.2M | 0.48% |
873,655
| – | – |
|
|
52
Tenet Healthcare
THC
$16.2B
| $12.1M | 0.47% |
+149,070
| New | +$12.1M |
|
53
BioNTech
BNTX
$24.2B
| $11.2M | 0.44% |
103,858
| – | – |
|
54
Neurocrine Biosciences
NBIX
$13.9B
| $10.6M | 0.42% |
112,908
| – | – |
|
55
Zimmer Biomet
ZBH
$21B
| $9.81M | 0.38% |
67,356
| – | – |
|
56
Rallybio
RLYB
$21.8M
| $9.78M | 0.38% |
1,727,067
| – | – |
|
57
Vaxcyte
PCVX
$4.11B
| $9.7M | 0.38% |
194,232
+189,232
| +3,785% | +$9.45M |
|
58
Alkermes
ALKS
$4.81B
| $9.69M | 0.38% |
309,613
| – | – |
|
59
Denali Therapeutics
DNLI
$2.25B
| $9.59M | 0.38% |
324,829
| – | – |
|
60
Avantor
AVTR
$9.07B
| $9.44M | 0.37% |
459,488
| – | – |
|
61
Omega Healthcare
OHI
$12.5B
| $9.4M | 0.37% |
306,433
| – | – |
|
62
United Therapeutics
UTHR
$18.9B
| $9.15M | 0.36% |
41,465
-19,735
| -32% | -$4.36M |
|
|
ITCI
63
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $8.32M | 0.33% |
131,435
-40,936
| -24% | -$2.59M |
|
64
Acadia Healthcare
ACHC
$2.07B
| $8.04M | 0.31% |
100,912
-85,575
| -46% | -$6.82M |
|
65
Madrigal Pharmaceuticals
MDGL
$9.87B
| $7.95M | 0.31% |
34,434
+21,953
| +176% | +$5.07M |
|
66
ResMed
RMD
$39.6B
| $7.58M | 0.3% |
34,704
-38,485
| -53% | -$8.41M |
|
|
HZNP
67
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $7.45M | 0.29% |
+72,425
| New | +$7.45M |
|
68
Inspire Medical Systems
INSP
$2.77B
| $7.15M | 0.28% |
+22,018
| New | +$7.15M |
|
69
Cytokinetics
CYTK
$5.61B
| $7.14M | 0.28% |
219,025
| – | – |
|
70
Steris
STE
$24B
| $6.99M | 0.27% |
31,072
| – | – |
|
71
Sanofi
SNY
$122B
| $6.65M | 0.26% |
123,454
| – | – |
|
|
RCM
72
DELISTED
R1 RCM Inc. Common Stock
RCM
| $6.58M | 0.26% |
356,851
| – | – |
|
73
CVS Health
CVS
$93.3B
| $6.47M | 0.25% |
93,621
| – | – |
|
74
Medpace
MEDP
$13.3B
| $6.46M | 0.25% |
26,918
+17,483
| +185% | +$4.2M |
|
75
Immunovant
IMVT
$2.58B
| $6.38M | 0.25% |
336,200
+220,800
| +191% | +$4.19M |
|